174 related articles for article (PubMed ID: 37230161)
41. Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.
Ott J
J Psychoactive Drugs; 2001; 33(4):403-7. PubMed ID: 11824699
[TBL] [Abstract][Full Text] [Related]
42. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors.
Halberstadt AL; Buell MR; Masten VL; Risbrough VB; Geyer MA
Psychopharmacology (Berl); 2008 Nov; 201(1):55-66. PubMed ID: 18604652
[TBL] [Abstract][Full Text] [Related]
43. Distribution of the hallucinogens N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method.
Barker SA; Littlefield-Chabaud MA; David C
J Chromatogr B Biomed Sci Appl; 2001 Feb; 751(1):37-47. PubMed ID: 11232854
[TBL] [Abstract][Full Text] [Related]
44. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
Riga MS; Soria G; Tudela R; Artigas F; Celada P
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1269-82. PubMed ID: 24650558
[TBL] [Abstract][Full Text] [Related]
45. Hallucinogens as discriminative stimuli: a comparison of 4-OMe DMT and 5-OMe DMT with their methythio counterparts.
Glennon RA; Young R; Benington F; Morin RD
Life Sci; 1982 Feb; 30(5):465-7. PubMed ID: 6801410
[TBL] [Abstract][Full Text] [Related]
46. Indolealkylamines and prolactin secretion. A structure-activity study in the central nervous system of the rat.
Seeman G; Brown GM
Neuropharmacology; 1985 Dec; 24(12):1195-200. PubMed ID: 3867833
[TBL] [Abstract][Full Text] [Related]
47. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
Jiang XL; Shen HW; Yu AM
Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
[TBL] [Abstract][Full Text] [Related]
48. Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.
Davis AK; Xin Y; Sepeda N; Averill LA
Am J Drug Alcohol Abuse; 2023 Sep; 49(5):587-596. PubMed ID: 37734158
[No Abstract] [Full Text] [Related]
49. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.
Halberstadt AL; Koedood L; Powell SB; Geyer MA
J Psychopharmacol; 2011 Nov; 25(11):1548-61. PubMed ID: 21148021
[TBL] [Abstract][Full Text] [Related]
50. Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.
Barker SA
Psychopharmacology (Berl); 2022 Jun; 239(6):1749-1763. PubMed ID: 35064294
[TBL] [Abstract][Full Text] [Related]
51. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice.
Jefferson SJ; Gregg I; Dibbs M; Liao C; Wu H; Davoudian PA; Woodburn SC; Wehrle PH; Sprouse JS; Sherwood AM; Kaye AP; Pittenger C; Kwan AC
Neuropsychopharmacology; 2023 Aug; 48(9):1257-1266. PubMed ID: 37015972
[TBL] [Abstract][Full Text] [Related]
52. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
53. A mechanistic insight for the biosynthesis of N,N-dimethyltryptamine: An ONIOM theoretical approach.
Coutinho LP; Silva SRB; de Lima-Neto P; Monteiro NKV
Biochem Biophys Res Commun; 2023 Oct; 678():148-157. PubMed ID: 37640000
[TBL] [Abstract][Full Text] [Related]
54. Intrathecal 5-methoxy-N,N-dimethyltryptamine in mice modulates 5-HT1 and 5-HT3 receptors.
Alhaider AA; Hamon M; Wilcox GL
Eur J Pharmacol; 1993 Nov; 249(2):151-60. PubMed ID: 7507056
[TBL] [Abstract][Full Text] [Related]
55. Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2010 Dec; 75(243):79296-300. PubMed ID: 21171485
[TBL] [Abstract][Full Text] [Related]
56. Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine.
Jacob MS; Presti DE
Med Hypotheses; 2005; 64(5):930-7. PubMed ID: 15780487
[TBL] [Abstract][Full Text] [Related]
57. Further studies on the mode of action of psychotomimetic drugs: antagonism of the excitatory actions of 5-hydroxytryptamine by methylated derivatives of tryptamine.
Bradley PB; Briggs I
Br J Pharmacol; 1974 Mar; 50(3):345-54. PubMed ID: 4277490
[TBL] [Abstract][Full Text] [Related]
58. Ontogeny of N,N-dimethyltryptamine and related indolealkylamine levels in neonatal rats.
Beaton JM; Morris PE
Mech Ageing Dev; 1984 Jun; 25(3):343-7. PubMed ID: 6588281
[TBL] [Abstract][Full Text] [Related]
59. 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study.
Ragnhildstveit A; Khan R; Seli P; Bass LC; August RJ; Kaiyo M; Barr N; Jackson LK; Gaffrey MS; Barsuglia JP; Averill LA
Front Psychiatry; 2023; 14():1271152. PubMed ID: 38076677
[TBL] [Abstract][Full Text] [Related]
60. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.
Krebs-Thomson K; Ruiz EM; Masten V; Buell M; Geyer MA
Psychopharmacology (Berl); 2006 Dec; 189(3):319-29. PubMed ID: 17013638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
